Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran

Abstract

Background:Oesophageal squamous cell carcinoma (ESCC) is a fatal disease with 5-year survival rates of <5% in Northern Iran. Oesophageal squamous dysplasia (ESD) is the precursor histologic lesion of ESCC. This pilot study was conducted to assess the feasibility, safety, and acceptability of non-endoscopic cytological examination of the oesophagus and to provide initial data on the accuracy of cytological atypia for identifying patients with ESD in this very-high-risk area.Methods:Randomly selected asymptomatic participants of the Golestan Cohort Study were recruited. A cytological specimen was taken using a capsule sponge device and evaluated for atypical cells. Sections of the cytological specimen were also stained for p53 protein. Patient acceptability was assessed using a visual analogue scale. The cytological diagnosis was compared with a chromoendoscopic examination using Lugol's solution.Results:Three hundred and forty-four subjects (43% male, mean (s.d.) age 55.6 (7.9) years) were referred to the study clinic. Three hundred and twelve met eligibility criteria and consented, of which 301 subjects (96.5%) completed both cytological and endoscopic examinations. There were no complications. Most of the participants (279; 92.7%) were satisfied with the examination. The sensitivity and specificity of the cytological examination for identifying subjects with high-grade ESD were 100 and 97%, respectively. We found an accuracy of 100% (95% CI=99–100%) for a combination of cytological examination and p53 staining to detect high-grade ESD.Conclusions:The capsule sponge methodology seems to be a feasible, safe, and acceptable method for diagnosing precancerous lesions of the oesophagus in this population, with promising initial accuracy data for the detection of high-grade ESD.

A prediction model for detection of esophageal squamous cell cancer: A new beginning or more of the same?

“…However, several less-invasive methods have been studied to screen for ESCC. Cytologic sampling with the Cytosponge (Medtronic, Minneapolis, Minn, USA), 19 serum biomarkers, 20,21 and breath tests 22 have also been studied in screening patients with ESCC, with promising preliminary data. As less-invasive and more cost-effective screening methods become available, the threshold of who should be screened may continue to evolve.…”

Role of TFF3 as an adjunct in the diagnosis of Barrett's esophagus using a minimally invasive esophageal sampling device—The CytospongeTM

“…Validation in a large cohort would be required to confirm that AI assessment of negative cases had a sufficiently high negative predictive value for these cases not to be screened by a pathologist. 44 Further studies are on-going to explore the potential of the Cytosponge TM test combined with molecular and/or immunohistochemical biomarkers to detect ESD. Squamous neoplasia was not identified in any of the BEST series of studies reflecting its very low incidence in the targeted patient populations.…”

“…43 A preliminary study in a population with a high prevalence of squamous cell carcinoma has shown the Cytosponge TM to be a feasible, safe and acceptable test for esophageal squamous dysplasia (ESD) with a sensitivity and specificity of 100% and 97% respectively when combined with p53 immunohistochemistry. 44 Further studies are on-going to explore the potential of the Cytosponge TM test combined with molecular and/or immunohistochemical biomarkers to detect ESD.…”

Enhancing High Value Care in Gastroenterology Practice

“…16 It may also be effective in screening for squamous cell carcinoma of the esophagus, the most common esophageal cancer worldwide. 17 …”